Top View
- A Randomized, Double-Blinded, Placebo-Controlled, Multicenter Trial
- Proportion of Japanese Outpatients Filling Prescriptions for Long-Term Medication Regimens
- Definitions of Gastroesophageal Reflux Disease (GERD) ���������������������� 1 Amit Patel and C
- Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant with the Use of Low-Dose Aspirin: a Prospective, Randomized, Placebo-Controlled Study
- Efficacy of Rebamipide in the Healing of Iatrogenic
- Rebamipide Protects Small Intestinal Mucosal Injuries Caused by Indomethacin by Modulating Intestinal Microbiota and the Gene Ex
- Pharmaabkommen A1 E
- Treatment Strategy for Chronic Gastritis in Asia
- Drug-Resin Complexes Stabilized by Chelating Agents
- Rebamipide, a Cytoprotective Drug, Increases Gastric Mucus Secretion in Human: Evaluations with Endoscopic Gastrin Test
- Preventive Efficacy and Safety of Rebamipide in Nonsteroidal Anti-Inflammatory Drug-Induced Mucosal Toxicity
- Effectiveness of Acid Suppressants and Other Mucoprotective Agents In
- Belching in Gastroesophageal Reflux Disease
- Gut Microbiota in NSAID Enteropathy: New Insights from Inside
- The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: an International Multicenter Study
- Malaysian Statistics on Medicines 2015-2016
- (2) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub
- Effect of Omeprazole, Rabeprazole, and Rebamipide on the Accuracy of Urea Breath Test in Patients with Helicobacter Pylori Infection
- Anti-Inflammatory Medications in the Treatment of Gastroesophageal Reflux Disease
- Acetaminophen (2 G and More) May Cause Upper Gastrointestinal
- Similar Efficacy of Ppis Vs H2ras in Reducing Risk of Upper GI Bleeding
- Rebamipide May Be Comparable to H2 Receptor Antagonist in Healing
- Potential Strategies in the Prevention of Nonsteroidal Anti-Inflammatory Drugs-Associated Adverse Effects in the Lower Gastrointestinal Tract
- A Double Capsule for the Administration of Active Principles in Multiple Therapies
- A Multicenter, Randomized, Controlled Trial of Rebamipide Plus Lansoprazole for the Treatment of Post-Endoscopic Submucosal Dissection Ulcers
- Potential Strategies in the Prevention of Nonsteroidal Anti-Inflammatory Drugs-Associated Adverse Effects in the Lower Gastrointestinal Tract
- Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors
- (12) United States Patent (10) Patent No.: US 6,350,468 B1 Sanso (45) Date of Patent: Feb
- Profile Often Divided; the Stem and Most of the Bark with the Peptic Ulcer Disease
- Overview of Gastroesophageal Reflux Disease Treatments Sabine Roman and Peter J
- Peptic Ulcer Disease
- Rebamipide with Proton Pump Inhibitors (Ppis) Versus Ppis Alone for the Treatment of Endoscopic Submucosal Dissection- Induced Ulcers: a Meta-Analysis